TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the marketing application of its Prednisolone Acetate, a chemical active pharmaceutical ingredient. This product is primarily used for treating allergic and autoimmune inflammatory diseases, and its approval is expected to enhance the company’s market position and provide significant benefits to stakeholders by expanding its product offerings in the pharmaceutical market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in China, operating in the pharmaceutical industry. The company focuses on the production and marketing of chemical active pharmaceutical ingredients, with a market emphasis on both domestic and international sectors.
Average Trading Volume: 2,163,129
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.72B
For an in-depth examination of 0719 stock, go to TipRanks’ Overview page.